Elizabeth Plimack, MD, MS, Fox Chase Cancer Center, Philadelphia, PA, discusses the updated analysis of the KEYNOTE-426 trial (NCT02853331). This study evaluated the efficacy and safety of pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for patients with advanced renal cell carcinoma (mRCC). Pembrolizumab in combination with axitinib continued to demonstrate superior and durable antitumor activity versus sunitinib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).